KMT2A and acute myeloid leukemia: These cases demonstrate the clinical utility of OGM, where a genome that was considered molecularly ‘normal’ was found to harbor genetic aberrations, including KMT2A and RUNX1 rearrangements, which are recognized as AML-defining genetic abnormalities.